Drug Profile
V 85546
Alternative Names: AS-111793; MMP-12 inhibitor - Merck Serono; V85546Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Merck Serono; Vernalis
- Developer Vernalis
- Class Anti-inflammatories
- Mechanism of Action Matrix metalloproteinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammation
Highest Development Phases
- Suspended Inflammation
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 16 Mar 2016 V 85546 is still available for licensing (http://vernalis.com)
- 12 Nov 2010 V 85546 is available for licensing for inflammatory disorders in World as of 22 Oct 2008. http://www.vernalis.com/